A
Acticor Biotech SA
PAR:ALACT
Acticor Biotech SA
PAR:ALACT
Price:
0.72 EUR
-7.69%
Market Closed
Updated:
May 31, 2024
Acticor Biotech SA
Income from Continuing Operations
|
Acticor Biotech SA
Income from Continuing Operations Peer Comparison
Comparables:
VLA
NANO
IPH
G
GNFT
ABVX
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
A
|
Acticor Biotech SA
PAR:ALACT
|
Income from Continuing Operations
-€18.6m
|
CAGR 3-Years
-72%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Income from Continuing Operations
-€76.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nanobiotix SA
PAR:NANO
|
Income from Continuing Operations
-€39.7m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-17%
|
|
|
Innate Pharma SA
PAR:IPH
|
Income from Continuing Operations
-€7.6m
|
CAGR 3-Years
-109%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-10%
|
|
G
|
Genfit SA
PAR:GNFT
|
Income from Continuing Operations
-€28.9m
|
CAGR 3-Years
34%
|
CAGR 5-Years
18%
|
CAGR 10-Years
-9%
|
|
|
Abivax SA
PAR:ABVX
|
Income from Continuing Operations
-€147.7m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
See Also
What is Acticor Biotech SA's Income from Continuing Operations?
Income from Continuing Operations
-18.6m
EUR
-18.6m
EUR
Based on the financial report for Jun 30, 2023, Acticor Biotech SA's Income from Continuing Operations amounts to -18.6m EUR.
What is Acticor Biotech SA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-47%
-47%
Over the last year, the Income from Continuing Operations growth was -33%. The average annual Income from Continuing Operations growth rates for Acticor Biotech SA have been -72% over the past three years , -47% over the past five years .
You don't have any saved screeners yet
